Skip To Main Content
Alexander Gaffney on Muck Rack

Alexander Gaffney

Verified
  • Executive Director, Regulatory Policy and Intelligence, POLITICO
Washington, D.C.
As seen in: POLITICO, LinkedIn, Regulatory Focus, AgencyIQ
Covers:  pharmaceuticals, pharmaceutical safety, fda, biologics, medical devices, ema, fda approvals, regulation
Doesn't Cover: health benefits, health insurance
Vice President of Regulatory Policy & Intelligence @Politico's @AgencyIQ. Tweeting about @US_FDA's regulation of #Pharma, #MedicalDevice, #Biotech.

Get in touch with Alexander

Contact Alexander, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Alexander Gaffney’s Biography

Read Full Bio →

News editor for Regulatory Focus, the online news publication of the Regulatory Affairs Professionals Society (RAPS). My areas of coverage include the regulation of pharmaceuticals, medical devices, biologics, regulatory agencies (FDA, EMA, MHRA, etc), legislative bodies and committees, and everything in between.

Online at www.RegulatoryFocus.org and on Twitter at @AlecGaffney.

Articles

Heidi Overton is Trump’s pick for next FDA commissioner. Here’s what to know.

|
By Alexander Gaffney Verified, Ned Pagliarulo
| AgencyIQ
President DONALD TRUMP plans to nominate White House policy aide HEIDI OVERTON as his next FDA commissioner. Here, AgencyIQ examines how Overton, a physician who has helped shape this administration’s health policy, might approach running the agency and identifies key questions ahead of her possible confirmation.
Open in Who Shared Issue with article?

Heidi Overton is Trump’s pick for next FDA commissioner. Here’s what to know.

|
By Alexander Gaffney Verified, Ned Pagliarulo
| AgencyIQ
By Alexander Gaffney, MS, RAC and Ned Pagliarulo President Donald Trump plans to nominate White House policy aide Heidi Overton as the next FDA commissioner, putting a figure closely involved in the administration’s health policy agenda in line to lead the agency. Beyond the nomination itself, her selection raises bigger questions about FDA’s regulatory direction, leadership and the future of initiatives already underway across the agency.
Open in Who Shared Issue with article?

More FDA leaders are departing. Here’s what the turmoil may mean for agency policies and priorities

|
By Laura DiAngelo, Alexander Gaffney Verified, Ned Pagliarulo
| AgencyIQ
Several of former FDA Commissioner MARTIN MAKARY’s top deputies are following their boss out the door or moving out of agency leadership. The shake-up signals HHS interest in a clean break from Makary and could carry consequences for some of the policies and projects he had touted.
Open in Who Shared Issue with article?
See all 53 articles